DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for vascular hemostatic disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleVascular hemostatic disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for vascular hemostatic disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
TNF receptor superfamily member 17 (TNFRSF17) — TNFRSF17 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-hydroxy-ethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4ZFO · 1.895 Å · ligand 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL (BTB). Experimental structure, not a prediction.
What the evidence adds up to
A 2015 prospective study of 60 patients undergoing total thyroidectomy compared the combination of harmonic scalpel plus an advanced haemostatic pad (Hemopatch) against harmonic scalpel plus standard haemostasis. The 24-hour drain output was lower in the Hemopatch group, and mean surgery time was shorter (p < 0.0001). The authors concluded the combination was effective and safe for thyroid surgery. No data on mortality, long-term outcomes, or use in other vascular haemostatic diseases were provided.
A 1995 letter to the editor noted that several vasodilators licensed for peripheral vascular disease or dementia were later shown to be clinically ineffective, and questioned their clinical value. The letter did not name any specific drug or present new trial data.
A 2025 review article on disorders of haemostasis, thrombosis, and haemorrhagic syndromes describes the physiological balance between bleeding and clotting, the pathogenesis of thrombotic and haemorrhagic conditions, and challenges in diagnosis and management. It mentions advances in diagnostic techniques and emerging therapeutic strategies but does not report any trial results, drug efficacy data, or specific repurposing candidates.
A 2023 book chapter on drug repurposing for cardiovascular disorders argues that repurposing reduces time investment and failure risk compared with de novo drug development. It does not present original data, name any repurposed drug, or report outcomes in any patient population.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Surgery · 2015 · 14 citations
Effectiveness of an advanced hemostatic pad combined with harmonic scalpel in thyroid surgery. A prospective study
AbstractINTRODUCTION: Hemostasis during thyroidectomy is essential; however the most efficient and cost-effective way to achieve this is unclear. The aim of this study was to evaluate the outcome of total thyroidectomy (TT) performed with the combination of harmonic scalpel (HS) and an advanced hemostatic pad (Hemopatch). METHODS: Patient undergone TT were divided into two groups: HS + hemopatch and HS + traditional hemostasis groups. The primary endpoint was 24-h drain output and blood-loss requiring reintervention. Secondary endpoints included surgery duration, postsurgical complications and hypocalcemia rates. RESULTS: Between September 2014 and March 2015, 60 patients were enrolled (30 to Hs + Hemopatch, 30 to Hs and standard hemostasis); 71.4% female; mean age 48.5 years. The 24-h drain output was lower in the HS + hemopatch group compared with standard TT. HS and hemopatch also had a shorter mean surgery time (p < 0.0001) vs standard TT. CONCLUSION: combination of hemopatch plus HS is effective and safe for TT with a complementary hemostatic approach.
Evidence supporting use of this drug has not yet been published
AbstractEDITOR,—There have been several instances of drugs being approved by licensing authorities and later shown to be clinically ineffective. Many vasodilators used for the treatment of peripheral vascular disease or dementia are still licensed in the United Kingdom (and probably elsewhere) but their clinical value is questionable.
Bush and colleagues refer to …
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
DISORDERS OF HEMOSTASIS THROMBOSIS HEMORRHAGIC SYNDROMES
AbstractThis article provides a comprehensive overview of disorders of hemostasis, focusing on thrombosis and hemorrhagic syndromes. Hemostasis is a critical physiological process that maintains the balance between bleeding and clot formation to preserve vascular integrity. Disruptions in this balance lead to either excessive clotting, causing thrombosis, or impaired coagulation, resulting in hemorrhagic conditions. The article discusses the basic mechanisms of hemostasis, the pathogenesis and clinical features of thrombosis and hemorrhagic syndromes, and highlights the challenges in diagnosis and management. Advances in diagnostic techniques and emerging therapeutic strategies are also reviewed, emphasizing the importance of individualized treatment approaches. The article aims to enhance understanding of hemostatic disorders and promote improved clinical outcomes through early recognition and effective intervention.
9 Drug repurposing strategy in the identification of drugs for cardiovascular disorders
AbstractCardiovascular disorders are considered a major health concern and the leading cause of death worldwide. New drug approvals for cardiovascular disorders have witnessed a sharp decline over the last few decades. The rationale development of new cardiovascular drugs, with improved therapeutic efficacy and lesser side effects, has been in progress over the years. Of note, the Drug repurposing strategy has proven to be the most effective and safe means of identification of new drugs. The drug repurposing strategy for cardiovascular disease has been of great value due to the reduction in time investment, lesser chances of failure, and the greater probability of getting an approved drug. A few reviews on the general topic of drug repurposing have been published. However, no comprehensive book chapter based on the drug repurposing strategy for cardiovascular disorders is reviewed. In the present book chapter, we have attempted to highlight the use of a drug repurposing strategy for the identification of new cardiovascular drugs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
